HCFA Needs to Do More to Prevent Medicare/Medicaid Fraud and Abuse

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 7
Volume 4
Issue 7

WASHINGTON--Medicare and Medicaid are hard pressed to stay ahead of profiteers bent on cheating the system administered by the Health Care Financing Administration (HCFA).

WASHINGTON--Medicare and Medicaid are hard pressed to stay aheadof profiteers bent on cheating the system administered by theHealth Care Financing Administration (HCFA).

Sarah F. Jaggar, director of health financing and policy issuesfor HCFA, testified before the House Subcommittee on Human Resourcesand Intergovernmental Relations that HCFA's fraud and abuse preventionprograms are weak.

She said that Medicare and Medicaid offer strong incentives forproviders to overprovide services, that HCFA has few controlsto detect questionable billing practices and too few limits onthe types of providers allowed to bill the federal agency, andthat there is little chance that profiteers will be prosecutedor will have to repay fraudulently obtained money.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content